New Insulins: Benefits and Challenges

Insulin degludec seemed to demonstrate a reduction in episodes of hypoglycemia, especially nocturnal hypoglycemia, by approximately 25% compared with insulin glargine, the FDA in its assessment highlighted the fact that this benefit was not a consistent feature seen across the different types of diabetes or definitions of hypoglycemia, in particular the more objective definitions of hypoglycemia .B enefits include flexibility of timing of insulin administration, the lack of weight gain or even weight loss, and some improvement in quality-of-life aspects.

 

 

 

 

<div style="&quot;text-align:" justify;"="">

 

 

 

 

 

 

 

 

 

    Related Conference of New Insulins: Benefits and Challenges

    September 29-30, 2026

    22nd World Congress on Endocrinology & Diabetes

    Paris, France
    October 20-21, 2026

    32nd World Diabetes & Heart Congress

    Amsterdam, Netherlands
    October 22-23, 2026

    4th World congress and Expo on Diabetes

    Toronto, Canada
    February 25-26, 2027

    20th International Summit on Diabetes

    London, UK
    March 23-24, 2027

    7th Annual Summit on Diabetes and Endocrinology

    Paris, France
    March 29-30, 2027

    8th Global summit on Diabetes and Endocrinology

    Amsterdam, Netherlands

    New Insulins: Benefits and Challenges Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in